Peoples Financial Services CORP. acquired a new stake in Zoetis Inc. (NYSE:ZTS – Get Rating) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 700 shares of the company’s stock, valued at approximately $132,000.
Other institutional investors have also bought and sold shares of the company. Ritholtz Wealth Management increased its position in shares of Zoetis by 40.0% during the first quarter. Ritholtz Wealth Management now owns 5,207 shares of the company’s stock worth $982,000 after purchasing an additional 1,487 shares in the last quarter. Stony Point Wealth Management Inc. increased its position in shares of Zoetis by 40.6% during the first quarter. Stony Point Wealth Management Inc. now owns 11,182 shares of the company’s stock worth $2,109,000 after purchasing an additional 3,230 shares in the last quarter. IAM Advisory LLC increased its position in shares of Zoetis by 53.9% during the first quarter. IAM Advisory LLC now owns 8,659 shares of the company’s stock worth $1,633,000 after purchasing an additional 3,033 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Zoetis by 12.9% during the first quarter. Pinnacle Bancorp Inc. now owns 3,151 shares of the company’s stock worth $594,000 after purchasing an additional 360 shares in the last quarter. Finally, Chesley Taft & Associates LLC increased its position in shares of Zoetis by 1.1% during the first quarter. Chesley Taft & Associates LLC now owns 22,123 shares of the company’s stock worth $4,157,000 after purchasing an additional 240 shares in the last quarter. Institutional investors and hedge funds own 90.73% of the company’s stock.
In other Zoetis news, Director Willie M. Reed sold 1,855 shares of the stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $162.31, for a total value of $301,085.05. Following the sale, the director now owns 6,782 shares of the company’s stock, valued at approximately $1,100,786.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roxanne Lagano sold 2,167 shares of the stock in a transaction dated Tuesday, April 26th. The shares were sold at an average price of $178.96, for a total value of $387,806.32. Following the completion of the sale, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,239,025.52. The disclosure for this sale can be found here. 0.12% of the stock is currently owned by corporate insiders.
ZTS has been the subject of several analyst reports. The Goldman Sachs Group dropped their target price on Zoetis from $237.00 to $208.00 and set a “buy” rating for the company in a report on Thursday, May 19th. Stifel Nicolaus dropped their target price on Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a report on Friday. Citigroup dropped their target price on Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a report on Wednesday, March 9th. Finally, StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $229.75.
ZTS opened at $174.61 on Monday. The stock’s 50-day moving average price is $168.99 and its 200 day moving average price is $191.68. Zoetis Inc. has a 12-month low of $154.18 and a 12-month high of $249.27. The company has a current ratio of 2.25, a quick ratio of 1.58 and a debt-to-equity ratio of 1.12. The firm has a market cap of $82.18 billion, a price-to-earnings ratio of 40.05, a PEG ratio of 2.93 and a beta of 0.77.
Zoetis (NYSE:ZTS – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.10. Zoetis had a return on equity of 49.62% and a net margin of 26.27%. The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same quarter in the prior year, the company earned $1.26 EPS. Zoetis’s revenue was up 6.9% on a year-over-year basis. On average, research analysts forecast that Zoetis Inc. will post 5.05 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Thursday, July 21st will be paid a dividend of $0.325 per share. This represents a $1.30 annualized dividend and a yield of 0.74%. The ex-dividend date is Wednesday, July 20th. Zoetis’s payout ratio is 29.82%.
Zoetis Profile (Get Rating)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Stories
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Get Rating).
Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net